bcli: the cashflow

MyFinsight

For the quarter ending 2025-09-30.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Total net cash provided by financing activities	6,100	5,787
Decrease in cash, cash equivalents and restricted cash	-135	654
Cash and cash equivalents at beginning of period	371	-
Cash and cash equivalents at end of period	236	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

For the quarter ending 2025-09-30.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Total net cash provided by financing activities	6,100	5,787
Decrease in cash, cash equivalents and restricted cash	-135	654
Cash and cash equivalents at beginning of period	371	-
Cash and cash equivalents at end of period	236	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

BRAINSTORM CELL THERAPEUTICS INC. (BCLI)